According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD.

This capital size is expected to provide sufficient support for the company’s ongoing operations, with the funding runway extending to the second half of 2029. It is worth noting that the strong cash reserves offer a solid foundation for Spyre Therapeutics to advance the research and development of its innovative therapies. Despite the challenging financing environment in the current biotechnology sector, the company continues to maintain a robust financial position.